Expertise in
11
conditions

Andre Cabie

Inserm CIC2504, Fort De France University Hospital, Fort De France, Martinique, 
Montpellier, FR 
Expertise in
11
conditions
Inserm CIC2504, Fort De France University Hospital, Fort De France, Martinique, 
Montpellier, FR 

Overview

Andre Cabie practices practicing medicine in Montpellier, France.

Mr. Cabie is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Zika Virus Disease, Togaviridae Disease, Chikungunya, and HIV/AIDS.

He is actively involved in clinical research, co-authoring 179 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Inserm CIC2504, Fort De France University Hospital, Fort De France, Martinique, Montpellier, France
Other Locations
Fort De France, France
Saint-quentin-les-marais, France
Paris, France
Nantes, France
Pierre-la-treiche, France
Saint-pierre-les-bois, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults
Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults
Enrollment Status: Completed
Publish Date: July 08, 2026
Intervention Type: Other, Drug
Study Drugs: Remdesivir, Lopinavir, Ritonavir, Interferon Beta-1A, Hydroxychloroquine, AZD7442
Study Phase: Phase 3
Temocillin Versus a Carbapenem as Initial Intravenous Treatment for Extended-spectrum Beta-lactamase Related Urinary Tract Infections, a Non-inferiority Study
Temocillin Versus a Carbapenem as Initial Intravenous Treatment for Extended-spectrum Beta-lactamase Related Urinary Tract Infections, a Non-inferiority Study
Enrollment Status: Completed
Publish Date: November 20, 2025
Intervention Type: Drug
Study Phase: Phase 3
Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') or or Authorisation for Early Access (AAP). A Prospective Cohort.
Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') or or Authorisation for Early Access (AAP). A Prospective Cohort.
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Other
Descriptive and Prognostic Study of Arbovirus Infections in France, Based on a Hospital Cohort of Children and Adults With Suspected Arbovirose.
Descriptive and Prognostic Study of Arbovirus Infections in France, Based on a Hospital Cohort of Children and Adults With Suspected Arbovirose.
Enrollment Status: Unknown
Publish Date: March 16, 2023
Intervention Type: Other
Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection.
Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection.
Enrollment Status: Terminated
Publish Date: March 21, 2022
Intervention Type: Other
Study Phase: Not Applicable
Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae
Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae
Enrollment Status: Unknown
Publish Date: June 06, 2018
Intervention Type: Drug
Study Drug: Temocillin
Study Phase: Phase 4
View 5 Less Clinical Trials

178 Total Publications

Autoantibodies neutralizing type I interferons underlie a third of cases of Chikungunya virus encephalitis or myelitis.
Autoantibodies neutralizing type I interferons underlie a third of cases of Chikungunya virus encephalitis or myelitis.
Journal: medRxiv : the preprint server for health sciences
Published: August 20, 2026

Frequently Asked Questions about Andre Cabie

Is Andre Cabie a top-rated expert for Zika Virus Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Andre Cabie is classified as an Distinguished expert for Zika Virus Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Andre Cabie participate in research or clinical trials?

Yes. Andre Cabie has published 178 articles and abstracts on conditions like Zika Virus Disease. You can view a list of Andre Cabie's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cabie's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 31 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile